Advanced Oncotherapy (AVO) said it had made ‘significant progress’ in its corporate objectives and maintained commercial momentum over the last 12 months despite the Covid-19 pandemic. Announcing its 2020 financial results, CEO Nicolas Serandour said it had been a pivotal year for the company, in which it had signed key commercial partnerships, secured a mix of…
©2023 All rights reserved LaingBuisson 
 said it had made ‘significant progress’ in its corporate objectives and maintained commercial momentum over the last 12 months despite the Covid-19 pandemic.){kind=link}